-
Cancer Costs US More Than $156 Billion Annually, With Drugs a Leading Expense Opens in a new window)
Care for the 15 most prevalent types of cancer in the U.S. cost approximately $156.2 billion in 2018, according to a team researchers. -
High-Expenditure Medicare Drugs Often Qualified for Orphan Drug Act incentives deSigned to Encourage the Development of Treatments for Rare Diseases
The Orphan Drug Act (ODA) provides financial incentives to encourage the development of drugs for rare diseases or conditions for which treatments might not be developed otherwise.Comments
-
Stemming the High and Rising Costs of Prescription Drugs
This initiative involves collaborating with decision makers and developing policies to reduce prescription drug spending without stifling innovation in the pharmaceutical industry.Comments
-
COVID-19 Pandemic Cut Life Expectancy by Most Since World War Two Opens in a new window)
Overall, men had more than a year shaved off in 15 countries, compared to women in 11 countries.Comments
-
Cost-Shifting in Drug Pricing, or the Lack Thereof Opens in a new window)
This analysis is part of the USC-Brookings Schaeffer Initiative for Health Policy, which is a partnership between Economic Studies at Brookings and the University of Southern California Schaeffer Center for Health Policy & Economics.Comments
-
Access to Cancer Medicines Deemed Essential by Oncologists in 82 Countries: An International, Cross-Sectional Survey Opens in a new window)
This international, cross-sectional survey was developed by investigators from a range of clinical practice settings across low-income to high-income countries, including members of the WHO Essential Medicines Cancer Working Group.Comments
-
ICER Releases Draft Evidence Report on Therapies for Severe Asthma
Tezepelumab for Severe AsthmaComments
-
Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation
This report makes the case that value-based pricing has the potential to better serve the American public by promoting research into drug products with greater clinical benefit that help meet the country’s health care needs.Comments
-
One Key Study Highlights How Cancer-Drug Prices Continue to Rise in the US — Even If They Don't Elsewhere Opens in a new window)
The study, published in July, found that between 2009 and 2019, 74% of the 65 cancer drugs the group looked at increased in price faster than the rate of inflation.Comments
-
Potential Savings for Medicare Part D Enrollees Under Proposals to Add a Hard Cap on Out-of-Pocket Spending Opens in a new window)
President Biden has endorsed adding a hard cap on out-of-pocket Medicare Part D prescription drug spending.Comments
-
Average Cost for COVID-19 ICU Patients Estimated at More Than $50,000 Opens in a new window)
The average cost of treating a COVID-19 patient who needs intensive care in Canada is estimated at more than $50,000, compared with $8,400 for someone who's had a heart attack.Comments
-
Price Differences To Insurers For Infused Cancer Drugs In Hospital Outpatient Departments And Physician Offices Opens in a new window)
Large savings are potentially available to commercial insurers from shifting cancer infusion care to nonhospital settings, but cost-sharing burdens could become very high for patients.Comments
-
Podcast: Pushing Against the QALY Criticism in Drug Pricing Opens in a new window)
QALY as a measurement has received a lot of criticism. It's been criticized in concept or in the specifics of how it's defined or used.Comments
-
A Framework for Categorizing and Analyzing Prescription Drug Pricing Reform Options Opens in a new window)
Nearly one in four Americans reports difficulty affording their prescription medication, and system-wide costs for payers are rising as well.Comments
-
Government Regulated or Negotiated Drug Prices: Key Design Considerations Opens in a new window)
Most Americans—79 percent—consider U.S. prescription drug prices to be unreasonable, with almost 3 in 10 reporting they go without prescribed medications because of cost.Comments
Comments